In the latest trading session, Pfizer (PFE) closed at $39.46, marking a +0.09% move from the previous day. The stock outpaced the S&P 500's daily loss of 0.22%. Meanwhile, the Dow lost 0.22%, and the Nasdaq, a tech-heavy index, lost 0.23%.
Prior to today's trading, shares of the drugmaker had lost 7.07% over the past month. This has lagged the Medical sector's loss of 5.31% and the S&P 500's gain of 4.87% in that time.
Wall Street will be looking for positivity from PFE as it approaches its next earnings report date. This is expected to be April 30, 2019. In that report, analysts expect PFE to post earnings of $0.77 per share. This would mark no growth from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $12.80 billion, down 0.84% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $2.86 per share and revenue of $52.83 billion. These totals would mark changes of -4.67% and -1.53%, respectively, from last year.
Any recent changes to analyst estimates for PFE should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.12% lower. PFE currently has a Zacks Rank of #3 (Hold).
Looking at its valuation, PFE is holding a Forward P/E ratio of 13.78. This valuation marks a discount compared to its industry's average Forward P/E of 14.31.
It is also worth noting that PFE currently has a PEG ratio of 2.38. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.16 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 18, putting it in the top 8% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE) : Free Stock Analysis Report
To read this article on Zacks.com click here.